CEFROXADINE DIHYDRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H19N3O5S.2H2O
Molecular Weight	401.435
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.[H][C@]12SCC(OC)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CCC=CC3)C(O)=O

InChI

InChIKey=WDYHZZPITKKPTD-OEDJVVDHSA-N

InChI=1S/C16H19N3O5S.2H2O/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8;;/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23);2*1H2/t10-,11-,15-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C16H19N3O5S
Molecular Weight	365.404
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373

Cefroxadine is an antibiotic developed for the treatment of bacterial infectious diseases caused by gram-negative and gram-positive organisms. The information about drug status is unavailable and is supposed to be "discontinued", however it may be manufactured in Italy by Novartis.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373	Curative		Approved 8429	ORASPOR Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

The daily dosage of 1000mg should be divided into 2 fractions and should be taken after breakfast and after supper.

Route of Administration: Oral

In Vitro Use Guide

The spectrum of antibacterial activity of cefroxadine against gram-positive and gram-negative bacteria was studied. About 0.005 ml of diluted culture was inoculated by Micro-planter onto agar plates containing a series of serial twofold dilutions of a drug. The concentration of the drug required to inhibit the growth of 50% of the total number of tested E. coli strains (MIC50) was 3.13 to 6.25 ug/ml. The MIC50 of cefroxadine against K. pneumoniae strains was 3.13 to 6.25 ug/ml.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:49:33 GMT 2023` Edited by `admin` on `Sat Dec 16 05:49:33 GMT 2023`
Record UNII	439L36E61V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFROXADINE DIHYDRATE

Common Name

English

CEFROXADINE DIHYDRATE [MI]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((AMINO-1,4-CYCLOHEXADIEN-1-YLACETYL)AMINO)-3-METHOXY-8-OXO-, DIHYDRATE, (6R-(6.ALPHA.,7.BETA.(R*)))-

Common Name

English

CEFROXADINE HYDRATE [JAN]

Common Name

English

Cefroxadine hydrate [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

439L36E61V